|

Safty and Efficacy of MCI Network Guided TMS for Early Alzheimer's Disease: A Randomized, Double-blind Trial

RECRUITINGN/ASponsored by Anhui Medical University
Actively Recruiting
PhaseN/A
SponsorAnhui Medical University
Started2025-07-20
Est. completion2025-12-30
Eligibility
Age45 Years – 85 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT07138677

Summary

Estimate the safty and efficacy of personalized network neuronavigated transcranial magnetic stimulations in early Alzheimer's disease patients

Eligibility

Age: 45 Years – 85 YearsHealthy volunteers accepted
Inclusion Criteria:

1. Subject diagnosed as either mild cognitive impairment due to AD or mild AD dementia based on National Institute on Aging-Alzheimer's Association criteria.
2. MMSE score 18-28.
3. CDR score 0.5-1.
4. On stable treatment with IAChE or memantine for at least 6 months.
5. Literate in Han Chinese.

Exclusion Criteria:

1. Recevied rTMS treatment in the past 3 months.
2. Depression or other psychiatric disorders.
3. History of head injury, stroke, epilepsy or other neurologic disease.
4. Organic brain defects on T1 or T2 images.
5. History of unexplained loss of consciousness.
6. Implanted pacemaker, medication pump, vagal stimulator, deep brain stimulator, or any implanted medical device that is incompatible with MRI.
7. Family history of medication refractory epilepsy.
8. History of substance abuse within the last 6 months.

Conditions4

Alzheimer's DiseaseAlzheimer's DiseaseIndividualized NavigationTranscranial Magnetic Stimulation

Browse More Trials

Alzheimer's Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.